127 related articles for article (PubMed ID: 37046179)
1. Establishment of
Man F; Yang Y; He H; Qi J; Wu W; Lu Y
Mol Pharm; 2023 May; 20(5):2579-2588. PubMed ID: 37046179
[No Abstract] [Full Text] [Related]
2.
Yang Y; Lv Y; Shen C; Shi T; He H; Qi J; Dong X; Zhao W; Lu Y; Wu W
Acta Pharm Sin B; 2021 Apr; 11(4):1056-1068. PubMed ID: 33996417
[No Abstract] [Full Text] [Related]
3. Salt Engineering of Aripiprazole with Polycarboxylic Acids to Improve Physicochemical Properties.
Afrooz H; Mohamed EM; Barakh Ali SF; Dharani S; Nutan MTH; Khan MA; Rahman Z
AAPS PharmSciTech; 2021 Jan; 22(1):31. PubMed ID: 33405012
[TBL] [Abstract][Full Text] [Related]
4. Preparation and characterization of dicarboxylic acids salt of aripiprazole with enhanced physicochemical properties.
Hamideh A; Rahman Z; Dharani S; Khuroo T; Mohamed EM; Nutan MTH; Reddy IK; Khan MA
Pharm Dev Technol; 2021 Apr; 26(4):455-463. PubMed ID: 33653226
[TBL] [Abstract][Full Text] [Related]
5. pH-Independent Dissolution and Enhanced Oral Bioavailability of Aripiprazole-Loaded Solid Self-microemulsifying Drug Delivery System.
Mahajan S; Singh D; Sharma R; Singh G; Bedi N
AAPS PharmSciTech; 2021 Jan; 22(1):24. PubMed ID: 33400035
[TBL] [Abstract][Full Text] [Related]
6. Aripiprazole-montmorillonite: a new organic-inorganic nanohybrid material for biomedical applications.
Oh YJ; Choi G; Choy YB; Park JW; Park JH; Lee HJ; Yoon YJ; Chang HC; Choy JH
Chemistry; 2013 Apr; 19(15):4869-75. PubMed ID: 23436433
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Compaction Force on the Transition to Hydrate of Anhydrous Aripiprazole.
Togo T; Taniguchi T; Nakata Y
Chem Pharm Bull (Tokyo); 2018; 66(3):263-269. PubMed ID: 29491260
[TBL] [Abstract][Full Text] [Related]
8. Enhanced dissolution and oral bioavailability of aripiprazole nanosuspensions prepared by nanoprecipitation/homogenization based on acid-base neutralization.
Xu Y; Liu X; Lian R; Zheng S; Yin Z; Lu Y; Wu W
Int J Pharm; 2012 Nov; 438(1-2):287-95. PubMed ID: 22989976
[TBL] [Abstract][Full Text] [Related]
9. Aripiprazole loaded poly(caprolactone) nanoparticles: Optimization and in vivo pharmacokinetics.
Sawant K; Pandey A; Patel S
Mater Sci Eng C Mater Biol Appl; 2016 Sep; 66():230-243. PubMed ID: 27207059
[TBL] [Abstract][Full Text] [Related]
10.
Taymouri S; Shahnamnia S; Mesripour A; Varshosaz J
Pharm Dev Technol; 2021 Oct; 26(8):867-879. PubMed ID: 34193009
[TBL] [Abstract][Full Text] [Related]
11. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
[TBL] [Abstract][Full Text] [Related]
12. Effect of sinapic acid on aripiprazole pharmacokinetics in rats: Possible food drug interaction.
Raish M; Ahmad A; Ansari MA; Alkharfy KM; Ahad A; Khan A; Aljenobi FI; Ali N; Al-Mohizea AM
J Food Drug Anal; 2019 Jan; 27(1):332-338. PubMed ID: 30648588
[TBL] [Abstract][Full Text] [Related]
13. Spectral and molecular modeling studies on the influence of β-cyclodextrin and its derivatives on aripiprazole-human serum albumin binding.
Yan J; Wu D; Ma X; Wang L; Xu K; Li H
Carbohydr Polym; 2015 Oct; 131():65-74. PubMed ID: 26256161
[TBL] [Abstract][Full Text] [Related]
14. In vitro dissolution-permeation evaluation of an electrospun cyclodextrin-based formulation of aripiprazole using μFlux™.
Borbás E; Balogh A; Bocz K; Müller J; Kiserdei É; Vigh T; Sinkó B; Marosi A; Halász A; Dohányos Z; Szente L; Balogh GT; Nagy ZK
Int J Pharm; 2015 Aug; 491(1-2):180-9. PubMed ID: 26117189
[TBL] [Abstract][Full Text] [Related]
15. The effect of resveratrol on pharmacokinetics of aripiprazole in vivo and in vitro.
Zhan YY; Liang BQ; Li XY; Gu EM; Dai DP; Cai JP; Hu GX
Xenobiotica; 2016; 46(5):439-44. PubMed ID: 26391142
[TBL] [Abstract][Full Text] [Related]
16. In vitro-in vivo correlations for three different commercial immediate-release indapamide tablets.
Yaro P; He X; Liu W; Xun M; Ma Y; Li Z; Shi X
Drug Dev Ind Pharm; 2014 Dec; 40(12):1670-6. PubMed ID: 24102615
[TBL] [Abstract][Full Text] [Related]
17. Effects of aripiprazole and haloperidol on progression to schizophrenia-like behavioural abnormalities and apoptosis in rodents.
Abekawa T; Ito K; Nakagawa S; Nakato Y; Koyama T
Schizophr Res; 2011 Jan; 125(1):77-87. PubMed ID: 20833512
[TBL] [Abstract][Full Text] [Related]
18. Morphological and Crystalline Transitions in Monohydrous and Anhydrous Aripiprazole for a Long-Acting Injectable Suspension.
Tan X; Zhong Y; He L; Zhang Y; Jing G; Li S; Wang J; He H; Tang X
AAPS PharmSciTech; 2017 May; 18(4):1270-1276. PubMed ID: 27480439
[TBL] [Abstract][Full Text] [Related]
19. Formulation of aripiprazole-loaded pH-modulated solid dispersions via hot-melt extrusion technology: In vitro and in vivo studies.
McFall H; Sarabu S; Shankar V; Bandari S; Murthy SN; Kolter K; Langley N; Kim DW; Repka MA
Int J Pharm; 2019 Jan; 554():302-311. PubMed ID: 30395959
[TBL] [Abstract][Full Text] [Related]
20. A Double-Blind and Placebo-Controlled Trial of Aripiprazole in Symptomatic Youths at Genetic High Risk for Bipolar Disorder.
Findling RL; Youngstrom EA; Rowles BM; Deyling E; Lingler J; Stansbrey RJ; McVoy M; Lytle S; Calabrese JR; McNamara NK
J Child Adolesc Psychopharmacol; 2017 Dec; 27(10):864-874. PubMed ID: 28759262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
